SK Biopharmaceuticals, a biotech company specializing in the research, development, and commercialization of treatments for central nervous system (CNS) disorders and oncology, has entered into a strategic research collaboration agreement with ProEn Therapeutics.
The partnership aims to enhance SK Biopharmaceuticals’ oncology research capabilities and broaden its pipeline of radiopharmaceutical therapies (RPT).
Research Collaboration to Accelerate RPT Development
The collaboration focuses on advancing up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027.
By that year, SK Biopharmaceuticals aims to become a global leader in the RPT field. The company is committed to strengthening both its internal and external resources to achieve this ambitious goal.
The joint research builds upon SK Biopharmaceuticals’ ongoing global strategic partnerships, which include the in-licensing of a radiopharmaceutical compound and a supply agreement for actinium-225, a key alpha-particle emitting radioisotope.
These efforts are part of SK Biopharmaceuticals’ “RPT Roadmap,” a strategy designed to secure a competitive advantage in the rapidly expanding nuclear medicine market.
Leveraging ProEn Therapeutics’ ArtBody Platform
A key component of this collaboration is SK Biopharmaceuticals’ use of ProEn Therapeutics’ ArtBody platform.
The dual-target binding technology incorporates small proteins to identify and target specific tumor antigens, enhancing tumor selectivity and minimizing damage to healthy tissues.
The ArtBody platform boasts intrinsic advantages such as high stability, structural robustness, and the ability to be mass-produced using bacteria, making it ideal for large-scale industrial applications.
Statements from Company Executives
Il-Han Lee, CEO of ProEn Therapeutics stated, “We are excited to enter this joint research effort and believe that the ArtBody platform will complement SK Biopharmaceuticals’ radiopharmaceutical therapy business. We are committed to achieving the best possible outcomes that meet both our expectations and the needs of patients”.
Donghoon Lee, CEO of SK Biopharmaceuticals mentioned, “This collaboration with ProEn Therapeutics is crucial, as the platform technology will help overcome the limitations of existing therapies. Our goal is to develop more effective and safer treatments while leading global RPT research and development efforts”.
The Brands
SK Biopharmaceuticals focuses on developing and commercializing treatments for CNS disorders and oncology. The company continues to strengthen its presence in the oncology sector through strategic collaborations and innovative research.
ProEn Therapeutics, a biotechnology firm dedicated to advancing oncology treatments, is at the forefront of protein engineering.
As reported by pharmabiz.com, the company’s ArtBody platform specializes in developing bi-specific antibody-drug conjugates tailored for the treatment of solid cancers.